We are thrilled to announce that Biocytogen will attend the World Bispecific Summit Europe from July 8th - 9th in London, UK. As the field is rapidly advancing, the focus is shifting toward more sophisticated antibody designs that enhance both efficacy and safety. Come visit us at Booth #4 to learn how our extensive line of animal models and systematic bioassays can advance your research.
What is the World Bispecific Summit Europe
The World Bispecific Summit Europe is a leading industry forum bringing together senior leaders to discuss the latest advances in bispecific and multispecific antibody therapeutics. Attendees will gain new insights on the next generation of T-cell engagers and bispecific ADCs through technical discussions and in-depth case studies.
Event Overview
Date: July 8th - 9th, 2026
Venue: Novotel London West, 1 Shortlands Hammersmith International Ctre, London W6 8DR, UK
Event Schedule
For more information, please refer to the event agenda.
About BIOCYTOGEN
Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, nanobody discovery and TCR mimic antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of June 30, 2025, approximately 280 therapeutic antibody and multiple clinical asset co-development/out-licensing/transfer agreements and over 50 target-nominated RenMice® licensing projects have been established around the globe, including several partnerships with multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.
We look forward to meeting you in London, UK!
